KCT0008491招募中Unknown
An Open-label, Phase 1b/2a Clinical trial to assess the Maximum Tolerated Dose (MTD), Safety and Efficacy of METi-101 in Patients with Refractory Metastatic Colorectal Cancer
MetiMedi Pharmaceuticals0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Females or males of age 19 or older at the time of consent acquisition
- •2) Histologically or cytologically confirmed colorectal adenocarcinoma
- •3) Patients with nonresectable metastatic lesions
- •4) Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 2
- •5) Patients with a life expectancy = 12 weeks as judged by the investigator
- •6) Patients with at least one measurable or evaluable lesion defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •7) Patients who meet the following criteria at screening:
- •? Bone marrow function
- •(1) Absolute Neutrophil Count (ANC) =1,500/mm^3
- •(2) Platelets =50,000/mm^3
- •? Renal function
- •(1) Serum creatinine =1.5 × Upper Limit of Normal (ULN)
- •(2) eGFR (Modification of Diet in Renal Disease, MDRD formula) =50mL/min/1.73m^2
- •? Hepatic function
- •(1) Alanine transaminase (ALT), Aspartate transaminase (AST) =5 × ULN
- •(2) Alkaline Phosphatase (ALP) =5 × ULN
- •(3) Total bilirubin =2 × ULN
- •8) Patients who have failed 2 or more palliative chemotherapies for metastatic colorectal cancer (treatment failure is defined not only as disease progression or recurrence after treatment, but also as intolerable side effects or failure to maintain treatment)
- •9) Voluntarily provided written consent to participate in this study
- •10) Patients who agree to contraception for 90 days or more for men and 30 days or more for women during the trial and after the end of the trial:
- •? Applicable to both female and female partners of male participants: intrauterine devices/tubal ligation for infertility purposes/combination of condoms or diaphragm with spermicide or contraceptives
- •? Applicable only to male participants (not applicable to male partners of female participants): condoms
- •? Absolute abstinence (intermittent abstinence such as during ovulation or symptothermal methods, or extracorporeal ejaculation do not apply if agreed upon as abstinence)
排除标准
- •1) History of malignancy other than metastatic colorectal cancer within 5 years prior to the first dose of investigational product (however, patients with effectively treated skin cancer, thyroid cancer, and carcinoma in situ that has been in complete remission for at least 3 years and thus considered cured by the investigator are eligible)
- •2) Uncontrolled CNS metastasis (however, patients with treated and stable brain metastasis (radiographically stable for at least 30 days) are eligible)
- •3) Complications related to primary cancer that require emergency surgery according to the judgment of the investigator.
- •4) Grade = 3 active infection requiring intravenous antibiotics per NCI-CTCAE version 5.0
- •5) History of one or more of the following cardiovascular diseases:
- •? cerebrovascular disease, unstable angina or myocardial infarction within 6 months of the screening visit.
- •? Congestive heart failure patients with New York Heart Association (NYHA) classification of Class III or higher.
- •? severe cardiac arrhythmias that cannot be controlled with medication or significant clinically abnormal cardiovascular findings as judged by the investigator
- •? QTc >480msec (Fredericia’s formula) on 12-lead ECG at the screening visit.
- •6) Renal disorder or chronic renal failure requiring blood or peritoneal dialysis.
- •7) History of obstructive urological diseases such as urolithiasis or urological tumors.
- •8) Pregnant women, breast-feeding women or women with a positive pregnancy test at screening visit
- •9) Previous treatment with the investigational product
- •10) Treatment with other investigational product within 30 days prior to the first dose of the investigational product
- •11) Patients who are otherwise considered to be ineligible for this study based on investigator’s judgment
研究者
相似试验
已完成
不适用
A phase I-II open label clinical trial, evaluating the efficacy and safety of administration of the therapeutic vaccine PEP-223/CoVaccine HT, to hormone treatment naive, immunocompetent subjects with T1-3, N0-1/x, M0 prostate cancer, eligible for hormone therapy.prostate cancerNL-OMON35662Pepscan Therapeutics B.V.12
尚未招募
不适用
A phase Ib, open-label, clinical trial to evaluate the safety, tolerability and immunogenicity of the Ebola chimpanzee adenovirus vector vaccines, vrc-eboadc069-00-vp (Cad3-Ebo) and vrc-eboadc076-00-vp (Cad3-Eboz), in healthy adults in Kampala, UgandaEbolaEbola Hemorrhagic FeverPACTR201412000957310S National Institute of Allergy and Infectious Diseases (NIAID)90
进行中（未招募）
1 期
A phase I-IIa clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced cancerAdvanced solid tumorsMedDRA version: 16.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2013-002663-25-NLVU University Medical Center27
已完成
不适用
A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumorsadvanced cancerAdvanced solid tumor10027655NL-OMON47883Vrije Universiteit Medisch Centrum27
招募中
不适用
Open-Label, Single arm, Phase II trial to evaluate efficacy and safety of Nivolumab as maintenance therapy following Platinum-based chemotherapy in non-small cell lung cancer patients after tyrosine kinase Inhibitor therapyNeoplasmsKCT0004541Asan Medical Center26